Malignant Pleural Mesothelioma - CuraGen And TopoTarget Announce Initiation Of NCI-sponsored Phase II

CuraGen And TopoTarget Announce Initiation Of NCI-sponsored Phase II
Medical News Today - Patients with unresectable malignant pleural mesothelioma, who have failed one prior line of chemotherapy, will be enrolled and receive PXD101 by intravenous infusion every three weeks. The primary endpoint for the study is response rate, with